# Anti-Integrin aVb6 [AvB6 53a.2]

Catalogue number: 151543 Sub-type: Primary antibody Images:

# Contributor

Inventor: John Marshall Institute: Queen Mary University of London Images:

## **Tool details**

#### **\*FOR RESEARCH USE ONLY**

Name: Anti-Integrin aVb6 [AvB6 53a.2]

#### Alternate name:

ZancerTools.org **Class:** Monoclonal Conjugate: Unconjugated Description: Monoclonal antibody involved in carcinoma invasion, with high potential as a therapeutic target. **Purpose:** Parental cell: **Organism: Tissue:** Model: Gender: **Isotype:** IgG2a Reactivity: Human Selectivity: Host: Rat Immunogen: Mouse fibroblasts retrovirally infected with cDNA to human beta6 (3T3b6.19). Cells expressed a mouse/human avb6 chimera. Immunogen UNIPROT ID: P06756 Sequence: Growth properties: **Production details:** Formulation: Recommended controls: BT20 breast carcinoma, original immunogen. **Bacterial resistance:** Selectable markers:

#### Additional notes:

### **Target details**

Target: Integrin alpha v/beta 6

#### Target alternate names:

Target background: Integrins are heterodimeric cell surface receptors composed of alpha and beta subunits, which mediate cell-cell and cell-extracellular matrix attachments. Changes in integrin expression have been shown to be important for the growth and early metastatic capacity of melanoma cells and aberrant integrin expression has been found in many epithelial tumours. The alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. Integrin alphav beta-6 is upregulated in cancers and during tissue remodelling but is absent from resting adult tissues. Integrin alpha-v beta-6 promotes carcinoma invasion, fibrosis and correlates with poor survival .Jes nc Cancer Tools.org and therefore makes a promising therapeutic target. This antibody does not recognize alpha V or other alpha V integrins.

#### Molecular weight:

Ic50:

# **Applications**

Application: FACS ; IF ; IP ; Fn **Application notes:** 

## Handling

Format: Liquid Concentration: 1 mg/ml Passage number: Growth medium: **Temperature:** Atmosphere: Volume: Storage medium: Storage buffer: PBS with 0.02% azide Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles Shipping conditions: Shipping at 4° C

### **Related tools**

**Related tools:** 

### References

**References:** Cao et al. 2007. J Biol Chem. 282(26):18922-8. PMID: 17470428. ; RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. ; Bacon et al. 2004. J Immunol. 173(2):1078-84. PMID: 15240696. ; Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. ; Chalupny et al. 2003. Biochem Biophys Res Commun. 305(1):129-35. PMID: 12732206. ; ULBP4 is a novel ligand for human NKG2D.

Cancer Tools.org